Transforming Weight Management Through Science
Viking Therapeutics introduces VK2735, an investigational, next-generation dual GLP-1/GIP receptor agonist designed to help adults achieve meaningful, sustained weight loss. Developed to address both obesity and overweight conditions with or without Type 2 Diabetes, VK2735 aims to make the complex seamless—bridging innovation, safety, and measurable efficacy.
Early clinical studies have demonstrated remarkable, dose-dependent reductions in body weight—up to 14.7%, with participants maintaining results long after treatment. VK2735 combines the proven power of incretin-based therapy with extended duration for convenient once-weekly dosing.
Join the movement toward a healthier future.